What are the risks of RSV infections for older individuals?
ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.
Article
Scientific Papers
Age, comorbidity burden and late presentation are significant predictors of hospitalization length and acute respiratory failure in patients with influenza
Influenza viruses are responsible for a high number of infections and hospitalizations every year.
Respiratory Syncytial Virus Infection in Older Adults: An Update
Respiratory syncytial virus (RSV) infection represents one of the most common infections during childhood, with significant morbidity and mortality in newborns and in the early years of life.
How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?
Respiratory syncytial virus (RSV) and influenza infections cause significant annual morbidity and mortality worldwide in at-risk populations.
Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection
Respiratory syncytial virus (RSV) infection can cause severe respiratory illness in older adults.
Host-microbe multiomic profiling reveals age-dependent immune dysregulation associated with COVID-19 immunopathology
It is well-established that older adults are at increased risk of severe and fatal COVID-19, but the mechanisms underlying this susceptibility are not entirely clear.
The influenza landscape and vaccination coverage in older adults during theSARS-Cov-2 pandemic: data from Several European Countries and Israel
While influenza and the common cold are both contagious viral respiratory tract illnesses, influenza can be a serious disease that could lead to severe complications and unfavorable outcomes due to broader consequences.
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Conclusions
Conclusions by Peter Openshaw, Co-Chair of the the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Science Policy Interface debate
How to ensure/prepare for access to immunisation programmes
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Rapporteur from the RSVVW’ 2024 meeting in Mumbai
By Ab Osterhaus, Host of the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: What's in the pipeline?
Live attenuated vaccines; NIRSE-GAL: Evaluation of the effectiveness and impact of Nirsevimab in Galicia; and Therapeutics
